Taiwan's ScinoPharm Builds New Manufacturing Plant in Jiangsu Province; Says Mainland's Stronger IP Environment, Growing Market Make It More Attractive
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Looking to leverage mainland China's production capacity and, potentially, its rapidly growing pharmaceutical market, Taiwan-based active pharmaceutical ingredients manufacturer ScinoPharm is building a new manufacturing facility in Jiangsu Province
You may also be interested in...
China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts
SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing
China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts
SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space